Therapeutics: targeting an oncometabolite.

Modeling cancer metabolism on a genome scale. Mol Syst Biol (2015) 0.92

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science (2013) 5.10

Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science (2013) 3.72

Interferon-gamma induces Fas trafficking and sensitization to apoptosis in vascular smooth muscle cells via a PI3K- and Akt-dependent mechanism. Am J Pathol (2006) 0.99

Glioblastoma: The histones have it. Nat Rev Cancer (2013) 0.97

Melanoma: Horses for courses. Nat Rev Cancer (2013) 0.96

Epigenetics. Going places with BANCR. Nat Rev Cancer (2012) 0.89

Metabolism: unmasking an oncometabolite. Nat Rev Cancer (2012) 0.85

Rapamycin inhibits human in stent restenosis vascular smooth muscle cells independently of pRB phosphorylation and p53. Cardiovasc Res (2005) 0.84

Regulatory RNA: layer by layer. Nat Rev Genet (2011) 0.83

Differential cyclin E expression in human in-stent stenosis smooth muscle cells identifies targets for selective anti-restenosis therapy. Cardiovasc Res (2003) 0.83

Cancer: Small losses, big gains with microRNAs. Nat Rev Genet (2010) 0.83

Leukaemia: MLL makes friends and influences. Nat Rev Cancer (2010) 0.83

Tumorigenesis: oncogene detox programme. Nat Rev Cancer (2011) 0.82

Tumorigenesis: All together now. Nat Rev Cancer (2013) 0.81

Autophagy: Directed development. Nat Rev Cancer (2014) 0.81

Metastasis: Influencing bad behaviour. Nat Rev Cancer (2009) 0.80

Retinoblastoma: Epigenetic outcome. Nat Rev Cancer (2012) 0.79

Cancer stem cells: Tracing clones. Nat Rev Cancer (2012) 0.79

Epigenetics: Worth another look? Nat Rev Cancer (2011) 0.79

Cell cycle: a WEE pointer. Nat Rev Cancer (2012) 0.79

Cell polarity: ASPP2 gets a polarity complex. Nat Rev Cancer (2010) 0.78

Tumour microenvironment: target practice. Nat Rev Cancer (2011) 0.78

Tumorigenesis: Megaphone MYC. Nat Rev Cancer (2012) 0.78

Tumour heterogeneity: Darwin's finches. Nat Rev Cancer (2012) 0.78

Tumorigenesis: WNT branches out. Nat Rev Cancer (2013) 0.78

Epigenetics. Layer by layer. Nat Rev Cancer (2011) 0.77

Epigenetics: the long view. Nat Rev Cancer (2013) 0.77

Chromatin remodelling: looking vulnerable. Nat Rev Cancer (2014) 0.77

Heterogeneity: A multidimensional overview. Nat Rev Cancer (2013) 0.77

Lung cancer: A surprising competitor. Nat Rev Cancer (2014) 0.77

Lung cancer: Gastric giveaways. Nat Rev Cancer (2013) 0.77

Prognostic models: rising to the challenge. Nat Rev Cancer (2013) 0.77

Metastasis: Twisting BMI1. Nat Rev Cancer (2010) 0.77

Anticancer drugs: Targeting menin. Nat Rev Drug Discov (2012) 0.77

Ubiquitylation: Mediation by degradation. Nat Rev Cancer (2013) 0.76

Tumour suppressors: Selective justice. Nat Rev Cancer (2011) 0.76

The ARTS of cell death. Nat Rev Cancer (2010) 0.76

Tumorigenesis. Better by half. Nat Rev Cancer (2012) 0.76

Signalling: REX rules. Nat Rev Cancer (2011) 0.76

Bladder cancer: seemingly similar. Nat Rev Cancer (2014) 0.76

Metabolism: a TIGAR tale. Nat Rev Cancer (2013) 0.76

Metastasis: Route master. Nat Rev Cancer (2009) 0.76

MicroRNA: lacking in maturity. Nat Rev Cancer (2013) 0.76

Drug resistance: making a point. Nat Rev Cancer (2013) 0.76

Systems biology: Lethal weaknesses. Nat Rev Cancer (2011) 0.76

Tumorigenesis: Cut here for differentiation. Nat Rev Cancer (2012) 0.76

Epigenetics: Showing a more sensitive side. Nat Rev Cancer (2013) 0.76

Pushing on through. Nat Rev Cancer (2010) 0.76

Metastasis: ADORA(2B)tion. Nat Rev Cancer (2013) 0.76

Stem cells: Self-sufficient. Nat Rev Cancer (2011) 0.75

Metastasis: Elf represses snail. Nat Rev Cancer (2012) 0.75

DNA damage: "Curiouser and curiouser!" cried Alice. Nat Rev Cancer (2010) 0.75

Leukaemia: 'Gimme shelter'. Nat Rev Cancer (2013) 0.75

Towards a mechanism. Nat Rev Cancer (2012) 0.75

Leukaemia: Knowing left from right. Nat Rev Cancer (2013) 0.75

Immunology: In need of a boost? Nat Rev Cancer (2010) 0.75

Metastasis: Going places with VHL. Nat Rev Cancer (2012) 0.75

Genomics: Viral vista. Nat Rev Cancer (2012) 0.75

DNA damage: In at the beginning. Nat Rev Cancer (2013) 0.75

Moving forwards. Nat Rev Cancer (2013) 0.75

DNA damage: The enemy within. Nat Rev Cancer (2012) 0.75

Drug resistance: Time for mediation? Nat Rev Cancer (2012) 0.75

Stem cells: Out for the count. Nat Rev Cancer (2010) 0.75

Mitochondria: Getting together. Nat Rev Cancer (2012) 0.75

Metabolism: Sensitivity to serine starvation. Nat Rev Cancer (2013) 0.75

Melanoma: More horses... Nat Rev Cancer (2013) 0.75

Metabolism: How sweet it is... . Nat Rev Cancer (2013) 0.75

Tumorigenesis: Replicating recurrence. Nat Rev Cancer (2009) 0.75

Finding your inner activator. Nat Rev Cancer (2010) 0.75

DNA damage: Running in parallel. Nat Rev Cancer (2013) 0.75

Stem cells: As directed. Nat Rev Cancer (2013) 0.75

Tumour suppression: Ejector seat. Nat Rev Cancer (2010) 0.75

Immunotherapy: Unlicensed to kill. Nat Rev Cancer (2012) 0.75

Proliferation: Multitasking. Nat Rev Cancer (2012) 0.75

Therapeutics: turnover. Nat Rev Cancer (2013) 0.75

Immunotherapy: Adapt and survive. Nat Rev Cancer (2012) 0.75

Signalling: Regulation and crosstalk. Nat Rev Cancer (2010) 0.75

Prostate cancer: understanding why. Nat Rev Cancer (2013) 0.75

Metabolism: Nuclear or cytoplasmic? Nat Rev Cancer (2013) 0.75

Medulloblastoma: origins. Nat Rev Cancer (2011) 0.75

Leukaemia: Early changes. Nat Rev Cancer (2012) 0.75

What's a girl to do? Nat Rev Cancer (2013) 0.75

Mitochondria: getting together. Nat Rev Mol Cell Biol (2012) 0.75

Cell death: A2B via p53. Nat Rev Cancer (2013) 0.75

Polarity: In the plane. Nat Rev Cancer (2013) 0.75

Leukaemia: Holding back. Nat Rev Cancer (2013) 0.75

Genomics: A broad brush. Nat Rev Cancer (2010) 0.75

Neuroendocrinology: Housing conditions affect tumour growth. Nat Rev Neurosci (2010) 0.75

Medulloblastoma: origins. Nat Rev Cancer (2011) 0.75

Immunotherapy: Unlicensed to kill. Nat Rev Immunol (2012) 0.75

Anticancer drugs: RAF complexities spark caution. Nat Rev Drug Discov (2010) 0.75

Tumorigenesis: Influencing those around you. Nat Rev Cancer (2012) 0.75

Therapeutics: Disrupting a survival signal. Nat Rev Cancer (2013) 0.75

Tumour suppression: Double act. Nat Rev Cancer (2010) 0.75

Epigenetics: WIP1 creates hush and havoc. Nat Rev Cancer (2013) 0.75

Glioblastoma: histone mutations take the MYCN. Nat Rev Cancer (2013) 0.75

Metastasis: No sympathy? Nat Rev Cancer (2012) 0.75

Signalling: YAP, PTEN and miR-29 size each other up. Nat Rev Cancer (2012) 0.75

Signalling: Keeping TABs on p53. Nat Rev Cancer (2013) 0.75

Macroenvironment: Stimulating resistance. Nat Rev Cancer (2010) 0.75

Therapeutics: Embracing instability. Nat Rev Cancer (2013) 0.75

Cell signalling: Regulation and crosstalk. Nat Rev Mol Cell Biol (2010) 0.75